fouremm

I had assumed that with a CVR the acquisitor has bought the company or the drug (e.g. apabetalone). Therefore, I also assumed, for example, that if the first milestone is met then the acquisitor pays out the agreed amount and those amounts are owned by each shareholder at the time of the agreed CVR deal. Then I assumed that if, for example, the second milestone is not met the acquisitor retains ownership of the drug and all payouts stop. Is this correct?

The second issue which I am somewhat confused about (it's obvious that I tend to be easily confused...hahaha) is why are we discussing a CVR now other than to clarify how it works?

Today we learned that BoM may be completed in 2019. In my opinion we have a very long way to go before any sort of CVR or any deal from a BP comes to fruition. From what I understand if the FA is positive and the trial continues that will be the one and only hint of efficacy of apabetalone until the end of the trial (am I wrong?) therefore what other facotrs could spark an acquisitor to make an offer. There are many factors including continuing good results from independent researchers, perceived competitive threats, further understanding of the MOA and pathways, etc.

Hepalink, if and when the PP is approved, will own 43% of RVX. Hepa is a Chinese pharma production company. I believe that Hepalink would have kicked the biochemical tires of rvx-208 and it's underlying epigenetic mechanisms as part of it's due diligence before their licensing deal. And I believe they have intimate understanding of all of the post hoc work published to date. And I believe they have been testing apabetalone in their own laboratories continuously. This is just my belief...complete conjecture. They just put in $87,000,000 pre FA. That is a pretty good signal they are very confident. Nobody else that we know of stepped up to the table.

I also believe that Hepalink has their chess game worked to 5 or 10 moves and Don might have 1 move at best. Just a hunch based on historical performance.

Hepalink essentially has controlling interest unless counterbalanced by an investor that is willing to provide the funding for all or some of the BoM trial plus, hopefully, the other trials. This is of course the big unknown and it must be resolved soon given the burn rate.

But as Kelsee pointed out...it just takes one (more) deal. And, of course that could happen.

Perhaps a positive FA will trigger Don's counterbalancing act. I sure hope so.

We've all be kept in the dark for a long time. I imagine Don is stressed and bruised these days.

So from my perspective, if Hepalink with their controlling interest in a company that they perceive is on the forefront of breakthrough science with (as Don claims) an 8 year intellectual and clinical trial lead on any other company in the world in a huge and growing market with unmet needs then Hepa will do anything to control it completely and that includes financing from Chinese gov't agencies.

My hope is that it will help the share price at some point.

I still believe strongly in the science and that epigenetic science will break though in terms of health care.

The big BPs may regret their inaction some day. Anyway, all just my opinions.

GLTA

Toinv